Benjamin J. Samelson-Jones, MD, PhD

Papers

2018

French RA, Samelson-Jones B., Niemeyer GP, Lothrop CD Jr, Merricks EP, Nichols TC, Arruda VR. Complete correction of hemophilia B phenotype by FIX-Padua skeletal muscle gene therapy in an inhibitor-prone dog model. Blood Adv. 2018 Mar 13;2(5):505-508.

Samelson-Jones B., Kramer PM, Chicka M, Gunning III WT, Lambert MP: MYH9-macrothrombocytopenia caused by a novel variant (E1421K) initially presenting as apparent neonatal alloimmune thrombocytopenia. Pediatric Blood and Cancer 2018.

Arruda VR, Doshi BS, Samelson-Jones B Emerging therapies for hemophilia: controversies and unanswered questions. F1000 Research 2018.

2017

George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones B., Ducore J, Cuker A, Sullivan LM, Majumdar S, Teitel J, McGuinn CE, Ragni MV, Luk AY, Hui D, Wright JF, Chen Y, Liu Y, Wachtel K, Winters A, Tiefenbacher S, Arruda VR, van der Loo JCM, Zelenaia O, Takefman D, Carr ME, Couto LB, Anguela XM, High KA. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. New England Journal of Medicine 377(23): 2215-2227, 2017.

Arruda VR, Doshi BS, Samelson-Jones B. Novel approaches to hemophilia therapy: successes and challenges. Blood 130(21): 2251-2256, 2017.

Herrmann A, Samelson-Jones B., Brake S, Samelson R.: IVIG-Associated Maternal Pancytopenia during Treatment for Neonatal Alloimmune Thrombocytopenia. American Journal of Perinatology Reports 7: e197-e200, 2017.

2016

Siner, J.I.*, and Samelson-Jones, B.*, Crudele, J.M., French, R.A., Lee, B.J., Zhou, S., Merricks, E., Raymer, R., Nichols, T., Camire R. M., Arruda V. R.  (2016) Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models.  Journal Clinical Investigation Insight: 16: e89371. (*contributed equally to work)

Arruda, V.R. and Samelson-Jones, B.  (2016) Gene Therapy for Hemophilia with Inhibitors.  Journal of Thrombosis and Haemostasis 14(6): 1121.

2015

Arruda, V.R. and Samelson-Jones, B. (2015) Obstacles and future of gene therapy for hemophilia.  Expert Opinion on Orphan Drugs  3:997-1010.

2006

Samelson-Jones B., Yeh S.R. (2006) Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry 45:8527-8538.

Wu Z., Jakes K.S., Samelson-Jones B., Lai B., Zhao G., London E., Finkelstein A. (2006) Protein translocation by bacterial toxin channels: a comparison of diphtheria toxin and colicin Ia. Biophys J. 91:3249-3256.

2000

Baluschev S., Friedman N., Khaykovich L., Carasso D., Johns B.*, and Davidson N. (2000) Tunable and frequency stabilized diode-laser with Doppler-free two-photon Zeeman lock.  Applied Optics 39: 4970-4974. (* The correct spelling should be Samelson-Jones B.)

Abstracts

2017

George LA, Ragni MV, Samelson-Jones B, Cuker A, Runoski AR, Cole G, Wright F, Chen Y, Hui DJ, Wachtel K, Takefman D, Couto LB, Reape KZ, Carr ME, Anguela XM, High KA: Spk-8011: Preliminary Results from a Phase 1/2 Dose Escalation Trial of an Investigational AAV-Mediated Gene Therapy for Hemophilia a. Blood 130: 604, 2017.

George LA, Sullivan SK, Giermasz A, Samelson-Jones B, Ducore JM, Teitel JM, Cuker A, Von Mackensen S, Majumdar S, McGuinn CE, Runoski AR, Wright F, Dasen S, Barber K, Chen Y, Hui DJ, Patel R, Liu Y, Wachtel K, Takefman D, Couto LB, Reape KZ, Carr CE, Anguela XM, High KA : Spk-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B - 1 Year Follow up and Impact of Baseline Characteristics on Transgene-Derived Factor IX Activity and Persistence. Blood 2017 130:601 130: 601, 2017.

Hui DJ, Liu Y, Patel R, Chen Y, George LA, Sullivan SK, Giermasz A, Rasko J, Samelson-Jones B, Ducore JM, Dasen S, Carr ME, Anguela XM, High KA: Spk-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B Achieves Sustained Factor IX with Minimal Immune Response. Blood 130: 2056, 2017.

Parsons NA, Ho MD, Davidson RJ, Thalji NK, Samelson-Jones B, Camire RM, George LA: Regulation of Factor VIII By Activated Protein C: Assessment In Vitro and In Vivo. Blood 130: 3650, 2017.

Samelson-Jones B, French RA, Crudele JM, Nichols TC, Arruda VR: The Role of Transgene Levels in Immune Tolerance Induction after AAV Gene Therapy in Hemophilia B Canine Models. Blood 130: 2057, 2017.

George, L.A., Sullivan, S.K., Giermasz, A, Ducore, J. M, Teitel, J.M., Samelson-Jones, B., Cuker, A, Sullivan, L.M., Majumdar, S., McGuinn, C.E., Galvao, A.M., Luk A.Y., Wright, J.F., Chen, Y., Hui, D.J., Wachtel, K., Galas, T., Takefman, D., Couto, L.B., Carr, M.E., Anguela, X.M., High, K.A. (April 2017) Initiation of Oral Steroid Therapy Produced Rapid Normalization of Transaminase Levels and Stabilization of FIX Activity in Subjects Who Developed Capsid Directed T-Cell Responses in the SPK-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B Phase 1/2 Trial.  Hemostasis and Thrombosis Research (HTRS) Annual Meeting. Scottsdale, AZ.

2016

Samelson-Jones B., Finn J. D., Camire R. M., Arruda V. R., (December 2016) New Hyperactive Factor IX Variants Bioengineered Based Upon Biochemical Studies of Factor IX Padua.  American Society of Hematology (ASH) Annual Meeting, San Diego, CA.

2015

Samelson-Jones B., Finn J. D., Raffini, L., Camire R. M., Arruda V. R. (June 2015) Investigations into Anticoagulant Resistance and Enhanced Activation as Putative Molecular Mechanisms of the Hyperactivity of Factor IX Padua. Congress of the International Society on Thrombosis and Haemostasis Congress (ISTH). Toronto, Canada  

Posters and Presentations

2017

Samelson-Jones, B., French R.A., Martin N.B., Nichols  T.C., Camire R.M., Arruda V.R. (July 2017) Immunogenicity and efficacy of FIX-Padua in distinct canine models of severe hemophilia B following AAV gene therapy to skeletal muscle or liver. Congress of the International Society on Thrombosis and Haemostasis (ISTH). Berlin, Germany

Samelson-Jones B., Siner J.I., Daniel, T.V.  Arruda, V.R. (July 2017) New Implications of the Deleterious Role of Furin Processing on Factor VIII Biology. Congress of the International Society on Thrombosis and Haemostasis (ISTH). Berlin, Germany.

2016

Samelson-Jones B., Finn J. D., Camire R. M., Arruda V. R., (November 2016) Rationally Designed Hyperactive Factor IX Variants Based Upon Biochemical Studies of Factor IX Padua. 45rd Annual Philadelphia Workshop on Hemostasis, Thrombosis and Atherosclerosis, Philadelphia, PA. 

Siner, J.I., Samelson-Jones, B., Crudele, J.M., French, R.A., Zhou, S., Merricks, E., Nichols, T., Camire R. M., Arruda V. R. (April 2016) Enhanced Hemophilia A Gene and Protein Therapy Using a Novel PACE/Furin Escaping Factor VIII Variant. Thrombosis and Hemostasis Summit of North America (THSNA), Chicago, IL.

2015

Siner, J.I., Samelson-Jones, B., Crudele, J.M., Zhou, S., Merricks, E., Nichols, T., Camire R. M., Arruda V. R. (November 2015) A Novel Furin-Evading Factor VIII Variant That Enhances Hemophilia A Therapy. 44rd Annual Philadelphia Workshop on Hemostasis, Thrombosis and Atherosclerosis, Philadelphia, PA. 

Siner, J.I., Samelson-Jones, B., Crudele, J.M., Zhou, S., Merricks, E., Nichols, T., Camire R. M., Arruda V. R. (June 2015) Enhanced Factor VIII Gene Therapy for Hemophilia A Dogs with a Novel Furin-Evading Factor VIII Variant. Congress of the International Society on Thrombosis and Haemostasis Congress (ISTH). Toronto, Canada